Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Petros Pharmaceuticals Inc

Healthcare US PTPI

0.008USD
-(-%)

Last update at 2026-03-10T19:20:00Z

Day Range

0.00720.008
LowHigh

52 Week Range

0.504.74
LowHigh

Fundamentals

  • Previous Close 0.008
  • Market Cap4.27M
  • Volume28944
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-10.20733M
  • Revenue TTM4.69M
  • Revenue Per Share TTM1.65
  • Gross Profit TTM 6.21M
  • Diluted EPS TTM-7.38

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -20.03757M -8.98668M -22.01292M -33.15717M -
Minority interest - - - - -
Net income -27.03757M -9.35534M -20.58592M -32.51130M -
Selling general administrative 12.21M 15.59M 15.67M 19.73M -
Selling and marketing expenses - - - - -
Gross profit 3.70M 6.21M 5.51M 8.15M -
Reconciled depreciation 5.60M 6.88M 6.66M 5.29M -
Ebit -15.84569M -18.04802M -17.28204M -16.86828M -7.69142M
Ebitda -6.84267M -11.17003M -10.62160M -11.57717M -
Depreciation and amortization 9.00M 6.88M 6.66M 5.29M -
Non operating income net other - - - - -
Operating income -15.84569M -18.04802M -17.28204M -16.86828M -
Other operating expenses 21.84M 25.86M 26.84M 32.45M -
Interest expense 0.60M 0.37M 3.05M 13.84M 0.00000M
Tax provision - 0.00000M -1.42699M -0.64587M -
Interest income 0.01M - - - -
Net interest income -0.58182M -0.36866M -3.05088M -13.84496M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 7.00M 0.37M -1.42699M -0.64587M -0.01337M
Total revenue 5.99M 7.81M 9.56M 15.58M -
Total operating expenses 19.55M 24.26M 22.80M 25.02M -
Cost of revenue 2.29M 1.60M 4.05M 7.43M -
Total other income expense net -4.19188M 9.06M -4.73088M -16.28889M -
Discontinued operations - - - - -
Net income from continuing ops -20.03757M -8.98668M -20.58592M -32.51130M -
Net income applicable to common shares - -8.98668M -20.58592M -32.51130M -32.47271M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 33.80M 32.42M 67.39M 69.85M 58.37M
Intangible assets 8.97M 25293.15M 25293.15M 32.16M 38.81M
Earning assets - - - - -
Other current assets 3.22M 0.80M 1.53M 1.42M 1.94M
Total liab 21.32M 15.72M 31.85M 52.38M 50.35M
Total stockholder equity 12.48M 16.70M 35.54M 17.47M 8.02M
Deferred long term liab - - - - -
Other current liab 5.73M 4.17M 26.42M 0.22M 0.45M
Common stock 0.00030M 0.00021M 0.00207M 0.00097M 29.12M
Capital stock 0.41M 0.00021M 0.00207M 0.00097M 49.14M
Retained earnings -98.88958M -90.72639M -70.68882M -61.70214M -41.11622M
Other liab - - 0.46M 9.96M 1.54M
Good will -8962.76526M -25280.90452M -25267.85585M - -
Other assets - - 11.03M 11.72M 6.73M
Cash 13.34M 9.43M 23.85M 17.14M 2.15M
Cash and equivalents - - - - -
Total current liabilities 10.77M 7.07M 30.98M 41.89M 41.10M
Current deferred revenue 2.05M - - 28.89M 30.19M
Net debt -5.06038M 0.31M -23.44255M -9.96467M 11.60M
Short term debt 1.28M 1.09M - 7.18M 6.68M
Short long term debt 1.16M 1.09M - 7.18M 6.68M
Short long term debt total 8.28M 9.74M 0.41M 7.18M 13.74M
Other stockholder equity 519.94M 107.43M 106.23M 79.17M 20.02M
Property plant equipment - 0.40M 0.52M 0.64M 0.74M
Total current assets 20.39M 14.67M 30.54M 25.91M 12.09M
Long term investments - - - - -
Net tangible assets - - 10.25M -14.69187M -50.81012M
Short term investments - - - - -
Net receivables 2.23M 2.11M 3.06M 5.15M 3.85M
Long term debt 6.86M 8.39M - - 7.06M
Inventory 1.61M 1.82M 0.52M 0.76M 2.20M
Accounts payable 1.71M 1.81M 4.56M 5.61M 3.78M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -408.98200M - - - -
Additional paid in capital - - - - -
Common stock total equity - - - 0.00097M 29.12M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.18M 5.11M 11.03M 11.14M 7.40M
Deferred long term asset charges - - - - -
Non current assets total 13.41M 17.75M 36.85M 43.95M 46.28M
Capital lease obligations 0.26M 0.26M 0.41M - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments - 0.00000M -0.00463M -0.07154M -
Change to liabilities 0.00000M -1.05159M 2.22M 2.02M -9.49367M
Total cashflows from investing activities - - -0.00463M -0.07154M -1.87566M
Net borrowings -1.62398M -7.18753M 8.78M -3.10925M -2.54776M
Total cash from financing activities -1.62398M 18.57M 30.30M -3.10925M -2.54776M
Change to operating activities - -3.67381M -5.80058M 7.58M 12.38M
Net income -20.03757M -8.98668M -20.58592M -32.51130M -32.47271M
Change in cash -14.42131M 6.71M 14.99M -0.64831M 3.60M
Begin period cash flow 23.85M 17.14M 2.15M 2.79M -
End period cash flow 9.43M 23.85M 17.14M 2.15M 2.79M
Total cash from operating activities -12.79733M -11.86203M -15.30532M 2.53M 8.02M
Issuance of capital stock 0.00000M 21.75M - - -
Depreciation 5.60M 6.88M 6.66M 5.29M 8.06M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -0.83532M 0.41M 0.73M 2.56M 0.10M
Change to account receivables 0.52M 2.55M -2.75036M 0.93M 1.95M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.00300M 4.01M 37.02M 2.90M 21.50M
Change to netincome 4.94M -8.00189M 4.18M 11.99M 25.67M
Capital expenditures 0.00000M 0.00000M 0.00463M 0.07M 1.88M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -3.30207M -1.76395M -5.60055M 13.09M -
Stock based compensation 1.20M 1.31M 3.63M 5.41M -
Other non cash items 3.75M 0.19M 2.02M 11.90M -
Free cash flow -12.79733M -11.86203M -15.30996M 2.46M -

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PTPI
Petros Pharmaceuticals Inc		 - -% 0.008 - - 0.98 0.47 0.19 -0.257
ZTS
Zoetis Inc		 -1.87 1.53% 120.49 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.56 2.23% 25.64 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.64 2.02% 128.01 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.14 0.77% 18.21 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Petros Pharmaceuticals Inc

1185 Avenue of the Americas, New York, NY, United States, 10036

Key Executives

Name Title Year Born
Mr. John D. Shulman Exec. Chairman 1963
Mr. Fady Boctor M.B.A. Principal Exec. Officer, Pres & Chief Commercial Officer 1978
Mr. Mitchell S. Arnold M.B.A. VP of Fin. & Chief Accounting Officer 1964
Mr. Robert Weinstein Interim Chief Financial Officer 1960
Mr. Keith F. Lavan Advisor 1964
Mr. John David Shulman Executive Chairman of the Board 1963
Mr. Fady Boctor M.B.A. President & Chief Commercial Officer 1978
Mr. Mitchell S. Arnold M.B.A. VP of Finance & Chief Accounting Officer 1964

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.